Cardiovascular disease (CVD) is the leading cause of death and disability worldwide. The
primary prevention of CVD is dependent upon the ability to identify high-risk individuals long …

The prevalence of heart failure (HF) due to cardiac remodelling after acute myocardial
infarction (AMI) does not decrease regardless of implementation of new technologies …

BACKGROUND Until recently, biomarker testing in heart failure (HF) syndromes has been
viewed as an elective supplement to diagnostic evaluation of patients suspected to suffer …

Heart failure is a clinical condition with complex pathophysiology that involves many
different processes. Diagnosis is often difficult in patients presenting for the first time with …

The use of risk markers has transformed cardiovascular medicine, exemplified by the routine
assessment of troponin, for both diagnosis and assessment of prognosis in patients with …

Cardiovascular diseases (CVDs) are a major healthcare burden on the population
worldwide. Early detection of this disease is important in prevention and treatment to …

Although substantial improvements have been made in majority of cardiac disorders, heart
failure (HF) remains a major health problem, with both increasing incidence and prevalence …

The last decade has seen exciting advances in the field of biomarkers used in managing
patients with heart failure (HF). Biomarker research has broadened our knowledge base …

Heart failure (HF) imposes significant economic and public health burdens upon modern
society. It is known that disturbances in neurohormonal status play an important role in the …

Aim: This study investigated the impact of the circulating galectin-3 level on the 30-day
prognostic outcome in patients with ST-segment elevation myocardial infarction (STEMI) …